Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The small molecule Chicago Sky Blue promotes heart repair following myocardial infarction in mice
Oren Yifa, … , Nenad Bursac, Eldad Tzahor
Oren Yifa, … , Nenad Bursac, Eldad Tzahor
Published November 14, 2019
Citation Information: JCI Insight. 2019;4(22):e128025. https://doi.org/10.1172/jci.insight.128025.
View: Text | PDF
Research Article Cardiology Therapeutics

The small molecule Chicago Sky Blue promotes heart repair following myocardial infarction in mice

  • Text
  • PDF
Abstract

The adult mammalian heart regenerates poorly after injury and, as a result, ischemic heart diseases are among the leading causes of death worldwide. The recovery of the injured heart is dependent on orchestrated repair processes including inflammation, fibrosis, cardiomyocyte survival, proliferation, and contraction properties that could be modulated in patients. In this work we designed an automated high-throughput screening system for small molecules that induce cardiomyocyte proliferation in vitro and identified the small molecule Chicago Sky Blue 6B (CSB). Following induced myocardial infarction, CSB treatment reduced scar size and improved heart function of adult mice. Mechanistically, we show that although initially identified using in vitro screening for cardiomyocyte proliferation, in the adult mouse CSB promotes heart repair through (i) inhibition of CaMKII signaling, which improves cardiomyocyte contractility; and (ii) inhibition of neutrophil and macrophage activation, which attenuates the acute inflammatory response, thereby contributing to reduced scarring. In summary, we identified CSB as a potential therapeutic agent that enhances cardiac repair and function by suppressing postinjury detrimental processes, with no evidence for cardiomyocyte renewal.

Authors

Oren Yifa, Karen Weisinger, Elad Bassat, Hanjun Li, David Kain, Haim Barr, Noga Kozer, Alexander Genzelinakh, Dana Rajchman, Tamar Eigler, Kfir Baruch Umansky, Daria Lendengolts, Ori Brener, Nenad Bursac, Eldad Tzahor

×

Figure 3

CSB improves cardiac function of adult mice following MI without inducing cardiomyocyte proliferation.

Options: View larger image (or click on image) Download as PowerPoint
CSB improves cardiac function of adult mice following MI without inducin...
(A) Schematic representation of the MI experiment timeline. (B) Cardiac ejection fraction (EF) of uninjured mice (n = 5), PBS-treated mice (n = 6), and CSB-treated mice (n = 9) up to 21 days after MI (mean ± SEM). (C) Cardiac fractional shortening (FS) of uninjured mice (n = 7), PBS-treated mice, (n = 8), and CSB-treated mice (n = 8) up to 21 days after MI (mean ± SEM). Statistical analysis for B and C was performed using 1-way ANOVA and Sidak’s correction. Asterisks represent the differences between PBS and CSB treatments. (D) Percentage of Ki67+ cardiomyocytes normalized to total cardiomyocytes in the heart of uninjured adult mice (n = 3) or in the border zone of PBS-treated (n = 5) or CSB-treated (n = 6) adult mice 4 days after MI (mean ± SEM, 1-way ANOVA and Tukey’s post hoc test). For all panels: *P < 0.05, **P < 0.01. NS, not significant; BL, baseline.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts